Principal Financial Group Inc. grew its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 1.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,820 shares of the biopharmaceutical company’s stock after acquiring an additional 1,482 shares during the period. Principal Financial Group Inc. owned about 0.26% of Bellicum Pharmaceuticals worth $991,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Clear Harbor Asset Management LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at approximately $118,000. Ronald Blue & Co. LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter valued at approximately $117,000. American International Group Inc. lifted its position in shares of Bellicum Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 852 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of Bellicum Pharmaceuticals during the 1st quarter valued at approximately $177,000. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of Bellicum Pharmaceuticals during the 1st quarter valued at approximately $177,000. Institutional investors own 55.73% of the company’s stock.
A number of equities research analysts have recently issued reports on BLCM shares. Ladenburg Thalmann Financial Services set a $31.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $32.00 price target on shares of Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Finally, BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $26.20.
ILLEGAL ACTIVITY WARNING: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/10/11/principal-financial-group-inc-boosts-stake-in-bellicum-pharmaceuticals-inc-blcm.html.
Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at 11.39 on Wednesday. The firm’s market capitalization is $378.44 million. Bellicum Pharmaceuticals, Inc. has a 12 month low of $7.41 and a 12 month high of $23.11. The company’s 50 day moving average price is $10.72 and its 200 day moving average price is $11.49.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter last year, the business earned ($0.61) EPS. Analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($3.02) EPS for the current year.
In related news, VP Ken Moseley sold 13,823 shares of the stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the completion of the sale, the vice president now directly owns 14,314 shares of the company’s stock, valued at $175,489.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 18.77% of the stock is owned by corporate insiders.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.